Triazoloquinazoline CDK4/6 Inhibitors for Solid Tumor Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors, particularly those targeting CDK4/6, face challenges such as lack of efficacy and high toxicity in solid tumors, as well as limited selectivity among CDK subtypes.
Innovation Solution
Development of 1H-[1,2,3]triazolo[4,5-h]quinazoline compounds that act as cyclin-dependent kinase (CDK) inhibitors, offering strong inhibitory activity and improved pharmacokinetic properties like metabolic stability and clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors are used to treat solid tumors, then CDK inhibition activity is achieved, but toxicity increases and efficacy is reduced
Solution Approach 1:
The patent introduces specific substituent groups (R1-R8) at different positions of the triazoloquinazoline core structure, where each position can be independently optimized to enhance CDK4/6 binding affinity while minimizing off-target effects. This localized optimization of molecular properties at specific positions resolves the contradiction between achieving strong inhibition and reducing toxicity.
Solution Approach 2:
The patent systematically varies multiple molecular parameters including substituent types, ring structures, and stereochemistry to optimize the balance between CDK inhibition potency and selectivity. By changing these parameters, the invention achieves compounds with enhanced therapeutic index, resolving the toxicity-efficacy contradiction.
2Adaptability or versatility
If non-selective CDK inhibitors are used, then broad CDK inhibition is achieved, but selectivity among CDK subtypes decreases leading to high toxicity
Solution Approach 1:
The patent optimizes specific regions of the molecule (R1-R8 substituents) to enhance interaction with the ATP-binding pocket of CDK4/6 while reducing affinity for other CDK subtypes. This localized optimization at key positions enables selective inhibition, resolving the contradiction between broad activity and subtype selectivity.
Solution Approach 2:
Instead of designing inhibitors that broadly target all CDKs and then filtering for selectivity, the patent inverts the approach by designing structures with inherent CDK4/6 selectivity from the outset through strategic substitution patterns, achieving both selectivity and broad therapeutic applicability.
3Reliability
If current CDK inhibitor compounds are developed, then CDK inhibition is achieved, but pharmacokinetic properties such as metabolic stability and clearance are insufficient
Solution Approach 1:
The patent modifies molecular parameters including the introduction of metabolically stable ring structures (R3-R8) and substitution patterns that resist enzymatic degradation. These parameter changes enhance metabolic stability and optimize clearance properties while maintaining CDK inhibition activity.
Solution Approach 2:
The patent creates composite molecular structures combining the triazoloquinazoline core with various stabilizing substituents and linkers that collectively enhance pharmacokinetic properties. This composite approach resolves the contradiction between maintaining inhibition activity and improving metabolic stability.
Data Source
AI summary
Provided in the present invention are 1H-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds of general formula (I), which can be used for treating cell proliferative disorders. The new compounds of the present invention are effective inhibitors of cyclin-dependent kinases (CDK).